Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Women's Health and Genetics/Laboratory Corporation of America, |
RCV001260326 | SCV001437253 | uncertain significance | not specified | 2020-09-21 | criteria provided, single submitter | clinical testing | Variant summary: MAN2B1 c.1893G>T (p.Gln631His) results in a non-conservative amino acid change located in the Glycosyl hydrolase family 38, C-terminal domain (IPR011682) of the encoded protein sequence. Three of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 0.00011 in 251456 control chromosomes (gnomAD). This frequency is not higher than expected for a pathogenic variant in MAN2B1 causing Alpha-Mannosidosis (0.00011 vs 0.0016), allowing no conclusion about variant significance. To our knowledge, no occurrence of c.1893G>T in individuals affected with Alpha-Mannosidosis and no experimental evidence demonstrating its impact on protein function have been reported. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014. Based on the evidence outlined above, the variant was classified as uncertain significance. |
Labcorp Genetics |
RCV001830061 | SCV003254408 | likely benign | Deficiency of alpha-mannosidase | 2024-02-17 | criteria provided, single submitter | clinical testing | |
Natera, |
RCV001830061 | SCV002086918 | uncertain significance | Deficiency of alpha-mannosidase | 2020-02-26 | no assertion criteria provided | clinical testing |